4. Menz V, Grimm W, Hoffmann J, Maisch B. Alcohol and rhythm disturbance: the holiday heart syndrome. *Herz* 1996;21:227–231.

5. Fukunami M, Yamada T, Ohmori M, Kumagai K, Umemoto K, Sakai A, Kondoh N, Minamino T, Hoki N. Detection of patients at risk for paroxysmal atrial fibrillation during sinus rhythm by P wave-triggered signal-averaged electrocardiogram. *Circulation* 1991;83:162–169.

6. Guidera SA, Steinberg JS. The signal-averaged P wave duration: a rapid and noninvasive marker of risk of atrial fibrillation. *J Am Coll Cardiol* 1993;21:1645–1651.

7. Klein MS, Evans SJL, Blumberg S, Cataldo L, Bodenheimer MM. Use of P-wave-triggered, P-wave signal-averaged electrocardiogram to predict atrial fibrillation after coronary artery bypass surgery. *Am Heart J* 1995;129:895–901.

8. Steinberg JS, Zelenkofske S, Wong SC, Gelernt M, Sciacca R, Menchavez E. Value of the P-wave signal-averaged ECG for predicting atrial fibrillation after cardiac surgery. *Circulation* 1993;88:2618–2622.

9. Ogawa H, Inoue T, Yoshida A, Doi T, Ohga N, Ohnishi Y, Yokoyama M. The signal-averaged electrocardiogram of P wave in patients with documented atrial fibrillation or flutter and in patients with left or right atrial overload without atrial fibrillation. *Jpn Heart J* 1993;34:29–39.

 ${\bf 10},$ Gondo N, Kumagai K, Matsuo K, Ogawa M, Annoura M, Moroe K, Arakawa K. The best criterion for discrimination between patients with and without

paroxysmal atrial fibrillation on signal-averaged electrocardiogram. *Am J Cardiol* 1995;75:93–95.

11. Stafford PJ, Turner I, Vincent R. Quantitative analysis of signal-averaged P waves in idiopathic paroxysmal atrial fibrillation. *Am J Cardiol* 1991;68:751–755.

12. Ishimoto N, Ito M, Kinoshita M. Signal-averaged P-wave abnormalities, and atrial size in patients with and without idiopathic paroxysmal atrial fibrillation. *Am Heart J* 2000;139:684–689.

13. Lander P, Berbari EJ, Lazarra R. Optimal filtering and quality control of the signal-averaged ECG. *Circulation* 1995;91:1495–1505.

14. Stafford PJ, Robinson D, Vincent R. Optimal analysis of the signal averaged P wave in patients with paroxysmal atrial fibrillation. *Br Heart J* 1995;74:413–418.

15. Cheema AN, Ahmed MW, Kadish AH, Goldberger JJ. Effects of autonomic stimulation and blockade on signal-averaged P wave duration. *J Am Coll Cardiol* 1995;26:497–502.

16. Stafford PJ, Cooper J, de Bono DP, Vincent R, Garratt CJ. Effect of low dose sotalol on the signal averaged P wave in patients with paroxysmal atrial fibrillation. *Br Heart J* 1995;74:636–640.

17. Engel TR, Luck JC. Effect of whiskey on atrial vulnerability and "holiday heart." J Am Coll Cardiol 1983;1:816-818.

18. Lüderitz B. Atrial fibrillation and atrial flutter: pathophysiology and pathogenesis. *Z Kardiol* 1994;83(suppl 5):1–7.

Effect of Short- and Long-Duration Spaceflight on QTc Intervals in Healthy Astronauts

Dominick S. D'Aunno, MD, Anne H. Dougherty, MD, Heidi F. DeBlock, MD, and Janice V. Meck, PhD

The human cardiovascular system undergoes profound changes when exposed to spaceflight, including cardiac rhythm disturbances during long-term missions.^{1–5} Underlying spaceflight-induced alterations in cardiovascular autonomic regulation may adversely influence cardiac repolarization and thus precipitate these rhythm disturbances.^{6–8} Therefore, we analyzed electrocardiograms or Holter monitor tracings obtained from astronauts who experienced short- and long-duration space missions. Our findings reveal striking differences in cardiac conduction and repolarization between short- and long-duration spaceflight.

Informed consent was obtained in accordance with the guidelines of the Committee for the Protection of Human Subjects at the Johnson Space Center. A retrospective analysis of electrocardiograms from 7 astronauts (6 men and 1 woman, average age 44 \pm 5 years for short-duration flights and 47 \pm 6 years for long-duration flights), who experienced both short-duration spaceflight onboard the space shuttle and long-duration spaceflight onboard Mir or the International Space Station, were used to measure PR, RR, and QT intervals. Threelead electrocardiograms were recorded during 1 minute of supine rest on digital tape 10 days before flight, on landing day (within 2 hours of touchdown), and 3 days after landing for short- and long-duration missions. One minute of data at rest was analyzed from lead II and the results averaged.

Twenty-four-hour Holter monitoring recordings from 3 crew members (3 men, average age 45 \pm 6 years) were obtained 60 days before launch, at 3 separate times during the mission (4-month flight), and 2 times after transfer to the space shuttle before re-entry on landing day (1 subject's Holter was recorded 2 days after landing) and at 11 or 39 days after landing. PR, RR, and QT intervals from lead V₂ were measured for 10 cardiac cycles at 1, 6, 11, and 16 hours. The results for each interval were averaged at each time period. Activity logs are not available.

The PR, RR, and QT intervals were measured manually, in random order, by 2 examiners blinded to flight duration or testing day. The beginning of the P wave and the beginning of the QRS complex defined the PR interval. The beginning of the Q (or R) wave and the end of the T wave at the isolectric point defined the QT interval. The QT interval was corrected for heart rate using Bazett's formula: $QTc = QT/(RR)^{0.5}$.

Electrocardiographic data from 1 long-duration astronaut were not collected 3 days after landing. Five of the 7 astronauts from long-duration spaceflights had complete electrocardiographic data sets available from previous short-duration spaceflights for comparison. Serum concentrations of potassium, calcium, and

From the National Space Biomedical Research Institute, Baylor College of Medicine, Houston, Texas; University of Texas Medical School at Houston, Houston, Texas; Albany Medical College, Albany, New York; and NASA-Johnson Space Center, Space and Life Sciences Directorate, Cardiovascular Laboratory, Houston, Texas. This report was supported by NASA Grant 96-OLMSA-01-051, Houston, Texas. Dr. Meck's address is: NASA-Johnson Space Center, Mail Code SK, Building 261, Cardiovascular Laboratory, Houston, Texas 77058. E-mail: jmeck@ems.jsc.nasa.gov. Manuscript received August 7, 2002; revised manuscript received and accepted October 9, 2002.

TABLE 1 Serum Electrolytes in Astronauts Before and After Spaceflight										
	Short Duration (n = 5)			Long Duration (n = 7)						
	Before Flight	Landing	After Flight	Before Flight	Landing	After Flight				
K ⁺ (mmol/L)	4.2 ± 0.10	4.2 ± 0.15	4.2 ± 0.09	4.2 ± 0.09	$3.8 \pm 0.09*$	4.1 ± 0.11				
Mg ⁺⁺ (mmol/L)	0.95 ± 0.05	0.95 ± 0.02	0.99 ± 0.03	1.1 ± 0.04	1.0 ± 0.03	1.0 ± 0.04				
Ca ⁺⁺ (mmol/L)	2.3 ± 0.05	2.4 ± 0.05	2.3 ± 0.06	2.4 ± 0.03	2.4 ± 0.04	2.4 ± 0.04				
+ -0.01										

*p <0.01.

Data are expressed as mean \pm SEM.

Serum concentrations of total calcium (Ca⁺⁺) potassium (K⁺), and magnesium (Mg⁺⁺) were obtained before flight, on landing day, and after flight (3 days after landing) for short- and long-duration spaceflight.



FIGURE 1. Individual QTc (*left*) and RR (*right*) intervals obtained from electrocardiograms recorded during 1 minute of supine rest, from a single male astronaut, before flight (*top*), and on landing day after short- (*middle*) and long- (*bottom*) duration flights.

magnesium were measured before flight, on landing day, and 3 days after landing.

Data were checked for normalcy and are expressed as mean \pm SEM. The coefficient of variation, a measure of relative variability, was calculated for RR and QTc intervals from 1 minute of electrocardiographic data obtained during supine rest before flight and on landing day, for short- and

long-duration spaceflights. A 2-way analysis of variance with repeated measures was used to determine if flight duration had an affect on PR, RR, and QTc intervals, coefficient of variation, and serum concentrations of potassium, calcium, or magnesium. Paired *t* tests were used to document differences when there was a significant main effect due to spaceflight duration. A p value <0.05 was considered significant.

Table 1 lists serum concentrations for potassium, calcium, and magnesium. Although there was a statistically significant decrease in the concentration of potassium on landing day after long-duration spaceflight (p = 0.002), clinically there were no changes in electrolyte levels sufficient to affect cardiac conduction or repolarization.

Figure 1 represents 1 minute of supine individual QTc and RR interval data for a single male astronaut before flight, and on landing day after short- and long-duration flight. After a short-duration flight, QTc intervals were not prolonged. After a long-duration flight, 24% of the QTc intervals were ≥ 0.45 second. The degree of variability of the QTc interval was increased in this subject after short and long missions. This is consistent with group findings that revealed an increase in the variability of QTc intervals on landing day after short-

and long-duration spaceflights (p = 0.03, p = 0.04). The coefficient of variation of the QTc intervals were 2.6 \pm 0.2% before flight, and 6.9 \pm 4.3% and 4.9 \pm 2.6% on landing day after short- and long-duration flight, respectively.

This subject had shorter RR intervals than those before flight after short and long flights, with the greatest decrease after the shorter flight. There were

 TABLE 2
 Electrocardiographic Intervals Before Flight, on

 Landing Day, and Three Days After Landing for Short- and
 Long-duration Spaceflights*

		Before Flight		Landing Day		After Flight				
Subject	Interval	SD	LD	SD	LD	SD	LD			
А	RR	1.36	1.17	1.07	1.30	1.04	0.79			
	PR	0.15	0.15	0.13	0.17	0.13	0.13			
	QT	0.40	0.43	0.43	0.43	0.39	0.36			
	QTc	0.37	0.35	0.37	0.42	0.37	0.41			
В	RR	1.10	1.03	0.68	1.07	1.04	0.83			
	PR	0.16	0.15	0.13	0.18	0.14	0.13			
	QT	0.36	0.36	0.32	0.41	0.37	0.36			
	QTc	0.35	0.36	0.38	0.40	0.36	0.40			
С	RR	NA	0.93	NA	0.93	NA	0.84			
	PR	NA	0.17	NA	0.18	NA	0.18			
	QT	NA	0.36	NA	0.38	NA	0.35			
	QTc	NA	0.37	NA	0.39	NA	0.38			
D	RR	NA	1.06	NA	0.97	NA	0.90			
	PR	NA	0.17	NA	0.19	NA	0.16			
	QT	NA	0.36	NA	0.38	NA	0.35			
	QTc	NA	0.35	NA	0.39	NA	0.37			
E	RR	0.87	0.88	0.73	1.07	1.05	NA			
	PR	0.17	0.17	0.14	0.19	0.17	NA			
	QT	0.36	0.36	0.33	0.41	0.39	NA			
	QTc	0.38	0.38	0.39	0.40	0.38	NA			
F	RR	0.96	0.94	0.85	0.88	0.92	0.80			
	PR	0.19	0.20	0.18	0.21	0.17	0.19			
	QT	0.38	0.37	0.35	0.38	0.37	0.36			
	QTc	0.39	0.37	0.37	0.41	0.39	0.40			
G	RR	0.99	1.01	0.80	0.87	1.12	0.85			
	PR	0.18	0.17	0.17	0.21	0.19	0.14			
	QT	0.37	0.36	0.32	0.35	0.38	0.35			
	QTc	0.38	0.35	0.36	0.39	0.36	0.38			
*PR, RR, QT, and QTc intervals (in seconds) from electrocardiograms re-										
corded during 1 minute of supine rest before and after both short- and										
long-duration spaceflights.										
LD = long-duration spaceflight; NA = no data available; SD = short-										
duration spaceflight.										

consistent intervals in the group. There was a trend toward greater RR interval variability after spaceflight, which was consistent with group findings. The degree of variability of the RR intervals obtained from 1 minute of supine rest before flight and on landing day showed a tendency toward an increase after short- and long-duration spaceflights (p = 0.05, p = 0.09).

Table 2 shows PR, RR, QT, and QTc intervals, and Figure 2 shows mean PR and QTc intervals measured from electrocardiograms obtained during 1 minute of supine rest before flight, on landing day, and 3 days after landing for short- and longduration spaceflights. Preflight PR, RR, and QTc intervals were similar for short- and long-duration spaceflights. PR intervals were decreased on landing day after short-duration spaceflight (p < 0.05, Figure 2). After a long-duration flight, PR and QTc intervals were significantly increased (p = 0.014, p = 0.012; Figure 2). The decrease in RR intervals observed on landing day after short-duration spaceflight was not present after long-duration spaceflight (p = 0.034).

Figure 3 shows mean PR, RR, and QTc intervals



FIGURE 2. PR (top) and QTc (bottom) intervals (mean \pm SEM) from electrocardiograms obtained during 1 minute of supine rest before flight, on landing day, and 3 days after landing for short-(left) and long- (right) duration spaceflight. *p <0.05; [†]p <0.01; [†]p <0.001.

measured from Holter monitoring recordings obtained before, during, and after long-duration spaceflight. Data were analyzed 4 times (at 5-hour intervals) for each 24-hour Holter recording. PR and QTc intervals were significantly increased during and after long-duration flight (p < 0.001, p < 0.001). This was consistent within each time period. Transfer from Mir to shuttle revealed a decrease in PR and QTc intervals (both were still greater than preflight values, p < 0.001), with little change in the RR interval. Onboard the shuttle, the PR and QTc intervals increased and were prolonged on landing day (p <0.001). The normal circadian variability in RR intervals was attenuated during shuttle day 1 and immediately after landing, but was present during all other test days.

The major finding of this study is that long-, but not short-, duration spaceflight prolongs cardiac conduction and repolarization. Shifts in sympathovagal balance and primary cardiac changes may be responsible. Long-duration flight is associated with QTc interval prolongation and may increase arrhythmia susceptibility. Medications that prolong



FIGURE 3. Mean PR, RR, and QTc intervals from 24-hour Holter recordings for 3 crew members before flight, during a 4-month space mission, after transfer to the space shuttle, on landing day, and 11 and/or 39 days after landing. $^{\dagger}p$ <0.001.

the QT interval should be administered with caution during and after long-duration spaceflight.

Acknowledgment: We would like to express our appreciation to the astronauts who volunteered to participate in this study and Mary Wear, MD, Epidemiology Section Supervisor of the Longitudinal Study of Astronaut Health, for providing data on electrolyte concentrations.

1. Fritsch-Yelle JM, Leuenberger UA, D'Aunno DS, Rossum AC, Brown TE, Wood ML, Josephson ME, Goldberger AL. An episode of ventricular tachycardia during long-duration spaceflight. *Am J Cardiol* 1998;81:1391–1392.

2. Pestov ID, Gerathewohl SJ. Weightlessness. In: Calvin M, Gazenko OK, eds. Foundations of Space Biology and Medicine. NASA SP-374, Washington, DC: US Government Printing Office, 1995:305–354.

3. Smith RF, Stanton K, Stoop D, Brown D, Janusz W, King P. Vectorcardiographic changes during extended space flight (MO93): observations at rest and during exercise. In: Johnston RS. Dietlein LF, eds. Biomedical Results from Skylab. Washington, DC: National Aeronautics and Space Administration, 1977:339–350.

4. Hoffler GW, Wolthuis RA, Johnson RL. Apollo space crew cardiovascular evaluations. *Aerosp Med* 1974;45:807–820.

5. Grigoriev AI, Egorov AD. Long-term flight. In: Nicgossian A, Mohler SR, Gazenko OG, Grigoriev AI, eds. Space Biology and Medicine: Joint U.S./ Russian. Reston, VA: American Institute of Aeronautics and Astronautics, 1996: 485–532.

6. Fritsch JM, Charles JB, Bennett BS, Jones MM, Eckberg DL. Short-duration spaceflight impairs human carotid baroreceptor-cardiac reflex responses. *J Appl Physiol* 1992;73:664–671.

7. Fritsch-Yelle JM, Charles JB, Jones MM, Beightol LA, Eckberg DL. Spaceflight alters autonomic regulation of arterial pressure in humans. *J Appl Physiol* 1994;77:1776–1783.

8. Fritsch-Yelle JM, Whitson PA, Bondar RL, Brown TE. Subnormal norepinephrine release relates to presyncope in astronauts after spaceflight. *J Appl Physiol* 1996;81:2134–to 2141.

Endothelial Dysfunction and Reduced Myocardial Perfusion Reserve in Heart Failure Secondary to Coronary Artery Disease

Richard M. de Jong, MD, Paul K. Blanksma, MD, Jan H. Cornel, MD, Ad F. M. Van den Heuvel, MD, Hans-Marc J. Siebelink, MD, Willem Vaalburg, PhD, and Dirk J. van Veldhuisen, MD

Diminished myocardial perfusion reserve¹⁻⁶ and endothelial dysfunction^{7,8} have been observed in patients with chronic heart failure. The aim of the present study was to examine a possible relation between severity of heart failure and perfusion and endothelial dysfunction in patients with left ventricular dysfunction. B-type natriuretic peptide (BNP) was measured as an objective measure of heart failure. Myocardial perfusion was assessed at rest during cold pressor testing (CPT) to assess endothelial function and during maximal vasodilation to assess perfusion reserve.

Patients satisfied the following inclusion criteria: men or women, 20 to 80 years old; left ventricular ejection fraction of <0.5, an old (>3 months) myocardial infarction, and no complaints of angina pectoris. Exclusion criteria were: hyper- or hypotension, hemodynamically significant valvular disease, pacemaker treatment, other serious illnesses, diabetes mel-

From the Department of Cardiology/Thoraxcenter, University Hospital Groningen, Groningen; Department of Cardiology, Medical Center Alkmaar, Alkmaar; and PET-center, University Hospital Groningen, Groningen, The Netherlands. Dr. de Jong was supported by the Netherlands Organization for Scientific Research (NWO), Den Haag, The Netherlands. Dr. Van Veldhuisen's address is: Department of Cardiology/Thorax Center, University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands. E-mail: D.J.Van. Veldhuisen@thorax.azg.nl. Manuscript received April 23, 2002; revised manuscript received and accepted October 11, 2002.